MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - November 06, 2012) - MorphoSys AG /
MorphoSys to Present Clinical Data on MOR103 at 2012 American College for
Rheumatology Annual Meeting.
Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
Company's late-breaking abstract to present data from the phase 1b/2a
trial evaluating its proprietary HuCAL antibody MOR103 in rheumatoid
at this year's American College for Rheumatology Annual Meeting has been
accepted. In addition to the safety and efficacy data published on
20th, MorphoSys today published supplementary data from the phase 1b/2a
including EULAR response rates, changes in DAS28 scores as well as RAMRIS
used to analyze MRI imaging in RA trials.
In the randomized, double-blind, placebo-controlled phase 1b/2a trial in 96
to moderate RA patients, MOR103 was administered in four weekly doses of
mg/kg, 1.0 mg/kg or 1.5 mg/kg. MOR103 showed excellent safety data at all
administered. With regards to efficacy, the trial was designed to look in
particular at the onset of the therapeutic effect. At week four, a
decrease of the DAS28 score was seen in the MOR103 group with a mean
of 1.12 and 0.61 in the 1.0 mg/kg and 1.5 mg/kg cohorts respectively, while
increase of 0.17 was documented for placebo. EULAR response criteria were
68.2% of the 1.0 mg/kg dose group and in 69.5% of the 1.5 mg/kg dose group
comparison to 7.4% in the placebo group. The clinical activity was mirrored
reduction in the RAMRIS score for joint swelling/synovitis of up to -1.5
"We are very excited about the opportunity to present the data at this
American College for Rheumatology meeting, the most relevant medical
for RA. This is a major milestone for us," commented Dr. Arndt Schottelius,
Chief Development Officer of MorphoSys AG. "The additional clinical data we
published today further underline the compound's potential to become an
important new drug in an area of unmet medical need."
The data will be presented by the principal investigator of the study,
Harald Burkhardt, Professor of Rheumatology and Head of the Division of
Rheumatology at Goethe University Frankfurt in a presentation session on
November 13, 2012.
The full abstract is available on http://www.acrannualmeeting.org/
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a
of MorphoSys AG.
This communication contains certain forward-looking statements concerning
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements
far as the wording of the relevant press release is concerned.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE